AXSM

117.14

0.13% 0.15

Dopo l'orario di chiusura: 117.14

Axsome Therapeutics Inc (AXSM)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché AXSM Giù? Forum Previsione

Precedente Chiudi:

$116.99

Aprire:

$116.99

Volume 24 ore:

463.77K

Relative Volume:

0.76

Capitalizzazione di mercato:

$5.85B

Reddito:

$338.46M

Utile/perdita netta:

$-310.96M

Rapporto P/E:

-17.94

EPS:

-6.53

Flusso di cassa netto:

$-132.82M

1 W Prestazione:

+7.71%

1M Prestazione:

+6.80%

6M Prestazione:

-14.96%

1 anno Prestazione:

+33.25%

Intervallo 1D:

$114.49

$117.29

Intervallo di 1 settimana:

$108.04

$117.29

Portata 52W:

$75.56

$139.13

Axsome Therapeutics Inc Stock (AXSM) Company Profile

Nome

Axsome Therapeutics Inc

Settore

Healthcare (1159)

Industria

Biotechnology (645)

Telefono

(212) 332-3241

Indirizzo

ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK

Dipendente

589

Cinguettio

Prossima data di guadagno

2025-02-18

Ultimi documenti SEC

AXSM's Discussions on Twitter

Confronta AXSM con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
AXSM Axsome Therapeutics Inc	117.14	5.55B	338.46M	-310.96M	-132.82M	-6.53
VRTX Vertex Pharmaceuticals Inc	397.46	99.96B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	598.16	60.83B	14.21B	4.46B	3.56B	39.68
ALNY Alnylam Pharmaceuticals Inc	467.55	59.89B	2.46B	-319.09M	-52.09M	-2.47
ARGX Argen X Se Adr	663.73	40.47B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	313.97	37.96B	3.81B	-644.79M	-669.77M	-6.24

Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-07-03	Ripresa	Morgan Stanley	Overweight
2025-06-03	Iniziato	Oppenheimer	Outperform
2025-04-07	Iniziato	Jefferies	Buy
2025-02-11	Iniziato	Deutsche Bank	Buy
2024-12-31	Reiterato	Mizuho	Outperform
2024-09-03	Iniziato	Wells Fargo	Overweight
2024-08-06	Aggiornamento	BofA Securities	Neutral → Buy
2024-07-22	Iniziato	Needham	Buy
2024-04-29	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2024-03-19	Iniziato	Robert W. Baird	Outperform
2024-02-06	Iniziato	UBS	Buy
2024-01-25	Iniziato	RBC Capital Mkts	Outperform
2023-12-13	Iniziato	Citigroup	Buy
2023-08-08	Aggiornamento	BofA Securities	Underperform → Neutral
2023-01-05	Iniziato	Piper Sandler	Neutral
2022-11-01	Iniziato	Loop Capital	Buy
2022-09-07	Ripresa	Mizuho	Buy
2021-08-10	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2021-06-10	Iniziato	Berenberg	Buy
2021-01-08	Iniziato	Jefferies	Buy
2020-12-16	Iniziato	Mizuho	Buy
2020-09-29	Iniziato	BofA Securities	Underperform
2020-09-10	Iniziato	Morgan Stanley	Overweight
2020-04-28	Reiterato	H.C. Wainwright	Buy
2020-04-14	Iniziato	Cowen	Outperform
2019-12-30	Reiterato	H.C. Wainwright	Buy
2019-12-17	Reiterato	H.C. Wainwright	Buy
2019-12-16	Reiterato	Guggenheim	Buy
2019-10-16	Iniziato	Guggenheim	Buy
2019-09-18	Iniziato	William Blair	Outperform
2019-05-28	Iniziato	SunTrust	Buy
2019-05-23	Reiterato	H.C. Wainwright	Buy
2019-04-08	Iniziato	SVB Leerink	Outperform
2019-03-15	Reiterato	H.C. Wainwright	Buy
2016-10-03	Ripresa	Brean Capital	Buy
2015-12-15	Iniziato	Cantor Fitzgerald	Buy
2015-12-14	Iniziato	Ladenburg Thalmann	Buy

Mostra tutto

Axsome Therapeutics Inc Borsa (AXSM) Ultime notizie

Aug 20, 2025

Axsome stock rating reiterated at Outperform by RBC, citing FDA flexibility - Investing.com

Aug 20, 2025

Vanguard Group Inc. Sells 25,537 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat

Aug 20, 2025

Wyckoff Accumulation Phase Possible in Axsome Therapeutics Inc.2025 Big Picture & Growth Focused Investment Plans - classian.co.kr

Aug 20, 2025

Fox Run Management L.L.C. Acquires 7,465 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat

Aug 20, 2025